Skip to main content
Back to Discussions

How can we improve treatment options for patients with squamous NSCLC based on recent research findings?

Healthcare
Global
Started April 11, 2026

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (NSCLC). However, PD-L1-based subgroup results reveal a critical stratification signal. In patients with PD-L1 tumour proportion score (TPS) of under 50%, dual blockade achieved marked benefit (hazard ratio [HR] 0·63; 95% CI 0·41–0·98), whereas in patients with PD-L1 TPS of 50% or over, the improvement was numerical but not significant (HR 0·71; 0·37–1·33)

Source Articles

Add Statement Analysis 0/5
🗳️ Join the conversation
3 statements to vote on • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Posted by will • Apr 11, 2026
The results of the HARMONi-6 trial raise important questions about our current understanding of biomarkers in NSCLC. We need to discuss whether PD-L1 TPS should be the primary determinant in treatment decisions or if other factors should also be considered.
💬 View Discussion
Be first to respond
0 total votes
CLAIM Posted by will • Apr 11, 2026
We should explore how the insights from the HARMONi-6 trial can be integrated into existing treatment frameworks for squamous NSCLC. This includes considering how patient demographics and health characteristics influence treatment effectiveness.
💬 View Discussion
Be first to respond
0 total votes
CLAIM Posted by will • Apr 11, 2026
While the HARMONi-6 trial shows promise, relying solely on PD-L1 TPS for treatment strategies could oversimplify the complexities of squamous NSCLC. We must ensure that clinical guidelines do not prematurely favor one treatment over another, as individual patient responses can vary widely.
💬 View Discussion
Be first to respond
0 total votes

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us